STOCK TITAN
  1. Home
  2. News
  3. BOLT

Bolt Biotherapeutics Inc - BOLT STOCK NEWS

IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
conferences
IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
clinical trial
IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
clinical trial
IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics to Participate in September Investor Conferences
conferences
IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
clinical trial
IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
conferences
IMPACT
SENTIMENT
BOLT : Nasdaq
BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases
IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
clinical trial
Stock BOLT logo
Bolt Biotherapeutics Inc
Nasdaq:BOLT

BOLT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About BOLT

bolt biotherapeutics is a start-up with compelling technology from dr. engleman’s lab at stanford university, which demonstrated complete cures in numerous cancer models. the company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.